Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, By Competition Forecast

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 230.02 Billion

CAGR (2023-2028)

6.25%

Fastest Growing Segment

Online Pharmacies

Largest Market

North America


Market Overview

Global Branded Generics Market has valued at USD 230.02 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2028. Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.

Key Market Drivers

Rising Patent Expirations

When the patent of a branded drug expires, generic drug manufacturers can legally enter the market and produce their own versions of the drug. This leads to increased competition, which often results in lower prices for consumers. As a result, more patients may switch to these affordable alternatives, driving the growth of the branded generics market. Patent expirations allow generic manufacturers to introduce their products in markets that were previously dominated by the branded drug. This can lead to increased access to essential medications in regions where cost was a barrier, thereby expanding the market. Branded generics are typically priced lower than their branded counterparts. This cost difference can provide significant savings for healthcare systems, especially in developing countries or regions with limited healthcare budgets. As a result, governments and healthcare providers might prefer to prescribe and purchase branded generics, further boosting the market's growth. The entry of multiple generic manufacturers after a patent expiration leads to increased competition within the market. This competition can drive innovation in terms of formulation, delivery methods, and packaging, as generic manufacturers strive to differentiate their products to gain a larger market share. In some cases, the introduction of numerous generic versions of a drug after patent expiry can lead to market saturation. As a result, the prices of generic versions can drop significantly due to intense competition. This can limit the revenue potential for generic manufacturers, but it benefits consumers and healthcare systems by providing more affordable options. The increased competition in the generic market can encourage manufacturers to invest in research and development to improve the quality, efficacy, and safety of their generic products. This focus on innovation can further enhance the growth of the branded generics market.

Growing Acceptance by Physician and Patient

Physicians' willingness to prescribe branded generics can directly impact their market growth. If physicians are confident in the quality and effectiveness of branded generics, they are more likely to prescribe them to their patients. Physician endorsement and confidence in the efficacy of branded generics can dispel concerns that patients might have about switching from a branded medication to a generic version. When physicians trust and recommend these alternatives, patients are more likely to accept and use them. Physicians often take into account the financial burden on their patients when prescribing medications. If physicians believe that branded generics offer similar therapeutic benefits as their branded counterparts, they may be more inclined to prescribe them to help patients save on healthcare costs. Pharmaceutical companies and healthcare institutions can play a role in educating physicians about the quality, safety, and equivalency of branded generics compared to branded drugs. Proper education can positively influence physicians' acceptance and prescribing habits. Patients may be concerned about switching from a well-known branded medication to a generic version. Positive experiences and successful treatment outcomes with branded generics can build patients' confidence in their effectiveness, leading to increased acceptance. Patients often trust their physicians' recommendations. If physicians explain the advantages of branded generics, including their affordability and equivalent therapeutic effects, patients are more likely to accept them. The cost factor is a significant driver of patient acceptance. Patients who cannot afford expensive branded medications may be more open to using branded generics as long as they are assured of their safety and efficacy.

Rising Incidence of Chronic Diseases

As the incidence of chronic diseases continues to rise globally, there is an increased demand for medications to manage these conditions. Branded generics offer cost-effective alternatives to branded drugs, making them more accessible to a larger population of patients who need continuous treatment. Chronic diseases often require long-term medication regimens, which can become financially burdensome for patients. Branded generics, being more affordable than their branded counterparts, are a viable option for patients looking to manage their conditions without straining their finances. Governments and healthcare systems are under pressure to provide affordable and sustainable healthcare services, especially for chronic disease management. Branded generics offer a way to reduce the overall cost of healthcare expenditures by providing effective treatment options at lower costs. The demand for chronic disease medications creates a competitive landscape for pharmaceutical companies. The expiration of patents for branded drugs used to manage chronic diseases opens up opportunities for generic manufacturers to enter the market with their branded generic versions. This competition can lead to innovation in formulations, delivery methods, and packaging, enhancing the growth of the branded generics market. Chronic diseases are not confined to a specific region; they affect populations worldwide. As such, the growth of the global branded generics market aligns with the need for accessible and affordable treatment options for chronic diseases in both developed and developing countries. Many chronic diseases are becoming increasingly prevalent in emerging markets due to lifestyle changes and aging populations. Branded generics cater to the demand for cost-effective treatments in these regions, driving market growth.

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles

Generic medications, including branded generics, need to go through regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.

Changing Healthcare Policies

Governments often implement pricing regulations to control healthcare costs and ensure affordability for patients. While these regulations can lead to lower prices for medications, they can also impact the profitability of generic manufacturers, including those producing branded generics. If pricing regulations result in extremely low profit margins, manufacturers might be discouraged from producing or promoting branded generics. Reimbursement policies determine how much of the cost of a medication is covered by insurance or government healthcare programs. Changes in reimbursement policies, such as reduced reimbursement rates for branded generics, can influence patient access and demand for these products. Healthcare policies can influence the inclusion or exclusion of specific medications on formularies, which are lists of drugs covered by insurance plans or healthcare systems. If branded generics are excluded from formularies due to policy changes, it can limit their market reach and growth potential. Some healthcare policies and guidelines encourage the use of generic medications over branded drugs to reduce costs. While this can benefit the healthcare system and patients, it might impact the market potential for branded generics, which are positioned as a bridge between branded and generic drugs. Changes in intellectual property laws or policies related to market exclusivity can affect the competitive landscape for branded generics. If policies extend market exclusivity periods for branded drugs, it can delay the entry of generic alternatives, including branded generics. Changing policies related to parallel imports (importing and selling branded generics from lower-cost markets) can impact the availability and pricing of branded generics in certain regions. Healthcare policies that lack clarity or transparency can lead to confusion among patients and healthcare professionals. This confusion might affect patient and physician acceptance of branded generics, hindering their market growth.

Key Market Trends

Advancements in Digital Health Integration

Digital health technologies can improve patient engagement by providing tools for medication reminders, tracking, and adherence. Branded generics, as more affordable alternatives, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for chronic disease management. Digital health solutions enable remote monitoring of patients' health conditions, which is particularly useful for managing chronic diseases. This integration can enhance patient compliance with medication regimens, contributing to the growth of the market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics. Branded generics can be tailored to fit individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can improve awareness of branded generics among patients and healthcare providers. Through digital platforms, manufacturers can educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can use data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns. This information can guide marketing strategies and product positioning for branded generics.

Development Biosimilars in the Branded Generics Landscape

Biosimilars compete with both the original biologic drugs and branded generics in some cases. This competition can drive down prices, making treatment more affordable for patients. The presence of biosimilars can put pressure on the pricing of branded generics, leading to increased adoption due to cost savings. Biosimilars can expand the market by providing more affordable options for patients who might have otherwise been unable to afford biologic treatments. This expanded patient base can also benefit branded generics by increasing awareness and demand for affordable alternatives. Biosimilars can capture a portion of the market share of both original biologics and branded generics. Depending on the competitive landscape, this redistribution can impact the growth of the branded generics market. The introduction of biosimilars can lead to increased awareness and education efforts around biologics and their alternatives. This increased education can benefit branded generics by creating a more informed market that understands the value of cost-effective options. The regulatory pathways developed for biosimilars can also impact regulations around generic medications, including branded generics. Changes in regulatory standards or guidelines for biosimilars might indirectly influence regulations for branded generics. As patients become more familiar with biosimilars and their benefits, they might become more open to considering alternative treatment options, including branded generics. Patient preferences and acceptance can be influenced by the broader context of biosimilar adoption.

Segmental Insights

Drug Class Insights

Based on the Drug Class, the Anti – Hypertensive segment is anticipated to witness substantial market growth throughout the forecast period. This growth can be attributed to multiple factors, such as Hypertension is a global health concern, affecting millions of people worldwide. As the prevalence of hypertension continues to rise due to factors like sedentary lifestyles and unhealthy diets, there is a growing need for accessible and cost-effective treatment options. Branded generics provide a solution by offering affordable alternatives to branded anti-hypertensive drugs. Hypertension is a chronic condition that often requires lifelong medication. Branded generics cater to the need for continuous treatment by providing affordable options for patients who may require long-term therapy. Governments and healthcare systems are under pressure to control healthcare costs. Branded generics can help healthcare systems manage their budgets more efficiently by providing cost-effective options for hypertension treatment. Many anti-hypertensive drugs have already lost their patent protection or are on the verge of patent expiry. This opens the door for generic manufacturers, including those producing branded generics, to enter the market and offer more affordable options.

Distribution Channel Insights

Based on the Distribution channel segment, the Retail Pharmacy segment has been the dominant force in the market. Retail pharmacies are essential for distributing medications, including branded generics, to patients. The presence of branded generics on pharmacy shelves makes them readily available and accessible to patients seeking affordable treatment options. Pharmacists at retail pharmacies provide patients with information about their medications, including branded generics. Pharmacists can educate patients about the benefits, cost savings, and effectiveness of branded generics, influencing their perception and acceptance. Retail pharmacies often work with insurance companies and healthcare systems to establish formularies, which are lists of approved medications. Including branded generics in these formularies can lead to increased prescriptions and market growth. Retail pharmacies are sensitive to patients' financial constraints. By offering branded generics as more affordable alternatives, pharmacies contribute to patient access and adherence to medications. In emerging markets with a significant retail pharmacy presence, branded generics can become essential for providing affordable treatment options to large populations.


Download Free Sample Report

Regional Insights

North America, specifically the Branded Generics Market, dominated the market in 2022, primarily due to North America has seen a significant number of patent expirations for blockbuster drugs, creating opportunities for generic manufacturers to introduce branded generic versions. As a result, the region has experienced substantial growth in the branded generics market as companies capitalize on these opportunities. The high healthcare costs in North America have driven the demand for more affordable alternatives to branded drugs. Branded generics provide a cost-effective option for patients and healthcare systems, contributing to their growth in the region. Branded generics address the need for accessible medications, particularly for chronic diseases that are prevalent in North America. They help patients manage their conditions without the financial burden of expensive branded medications. The presence of health insurance systems in North America, including private insurance and government programs like Medicare and Medicaid, can encourage the use of more affordable branded generics by providing coverage for these medications.

Recent Developments

  • In March 2023, United Nations-backed Medicines Patent Pool (MPP) has granted Viatris, Inc., Aurobindo Pharma, and Cipla Inc. sublicenses to make low-cost branded generic versions of Apretude, a HIV drug manufactured by GSK plc. ViiV, a company established by a joint venture of GSK plc. and Pfizer Inc., will help the companies with the development, production, and supply of the branded generic versions.
  • In May 2021, Teva Pharmaceutical Industries Ltd. announced the release of the first generic version of THIOLA® (tiopronin) tablets in the United States. These tablets are intended to be used in conjunction with high fluid intake, alkali, and diet modification to prevent the formation of cystine (kidney) stones in adults and pediatric patients with severe homozygous cystinuria who are older than nine years old and who are not responsive to these treatments alone.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals Inc.
  • Sanofi-Aventis.
  • Sun Pharmaceutical Industries Inc.
  • Dr Reddy's Laboratories Inc.
  • Endo International PLC.
  • GlaxoSmithKline LLC.
  • Pfizer Inc.
  • Viatris Inc.
  • Apotex Inc.

 By Drug Class

By Application

By Distribution Channel

By Region

Alkylating Agents

Antimetabolites, Hormones

Anti – Hypertensive

Lipid Lowering Drugs

Antidepressant

Antipsychotics

Antiepileptics

Others

Oncology

Cardiovascular Diseases

Neurological Diseases

Acute & Chronic Pain

Gastrointestinal Diseases

Dermatological Diseases

Others  

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy  

North America

Europe

Asia Pacific

South America

Middle East & Africa

Report Scope:

In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

            ·         Branded Generics Market, By Drug Class:

o   Alkylating Agents

o   Antimetabolites, Hormones

o   Anti – Hypertensive

o   Lipid Lowering Drugs

o   Antidepressants

o   Antipsychotics

o   Antiepileptics

o   Others

            ·         Branded Generics Market, By Application:

o   Oncology

o   Cardiovascular Diseases

o   Neurological Diseases

o   Acute & Chronic Pain

o   Gastrointestinal Diseases

o   Dermatological Diseases

o   Others

            ·         Branded Generics Market, By Distribution Channel:

o   Hospital Pharmacy

o   Retail Pharmacy

o   Online Pharmacy  

            ·         Branded Generics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.

Available Customizations:

Global Branded Generics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Branded Generics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Branded Generics Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)

5.2.2.    By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)

5.2.3.    By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

5.2.4.    By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.5.    By Company (2022)

5.3.  Market Map

5.3.1 By Drug Class

5.3.2 By Application

5.3.3 By Distribution Channel

5.3.4 By Region

6.    North America Branded Generics Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)

6.2.2.    By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)

6.2.3.    By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Branded Generics Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.            By Drug Class

6.3.1.2.2.            By Application

6.3.1.2.3.            By Distribution Channel

6.3.2.    Canada Branded Generics Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.            By Drug Class

6.3.2.2.2.            By Application

6.3.2.2.3.            By Distribution Channel

6.3.3.    Mexico Branded Generics Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.            By Drug Class

6.3.3.2.2.            By Application

6.3.3.2.3.            By Distribution Channel

7.    Europe Branded Generics Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)

7.2.2.    By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)

7.2.3.    By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France Branded Generics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Drug Class

7.3.1.2.2.            By Application

7.3.1.2.3.            By Distribution Channel

7.3.2.    Germany Branded Generics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Drug Class

7.3.2.2.2.            By Application

7.3.2.2.3.            By Distribution Channel

7.3.3.    United Kingdom Branded Generics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.            By Drug Class

7.3.3.2.2.            By Application

7.3.3.2.3.            By Distribution Channel

7.3.4.    Italy Branded Generics Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.            By Drug Class

7.3.4.2.2.            By Application

7.3.4.2.3.            By Distribution Channel

7.3.5.    Spain Branded Generics Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.            By Drug Class

7.3.5.2.2.            By Application

7.3.5.2.3.            By Distribution Channel

8.    Asia-Pacific Branded Generics Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)

8.2.2.    By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)

8.2.3.    By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Branded Generics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Drug Class

8.3.1.2.2.            By Application

8.3.1.2.3.            By Distribution Channel

8.3.2.    India Branded Generics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Drug Class

8.3.2.2.2.            By Application

8.3.2.2.3.            By Distribution Channel

8.3.3.    Japan Branded Generics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Drug Class

8.3.3.2.2.            By Application

8.3.3.2.3.            By Distribution Channel

8.3.4.    South Korea Branded Generics Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Drug Class

8.3.4.2.2.            By Application

8.3.4.2.3.            By Distribution Channel

8.3.5.    Australia Branded Generics Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Drug Class

8.3.5.2.2.            By Application

8.3.5.2.3.            By Distribution Channel

9.    South America Branded Generics Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)

9.2.2.    By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)

9.2.3.    By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Branded Generics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Drug Class

9.3.1.2.2.            By Application

9.3.1.2.3.            By Distribution Channel

9.3.2.    Argentina Branded Generics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Drug Class

9.3.2.2.2.            By Application

9.3.2.2.3.            By Distribution Channel

9.3.3.    Colombia Branded Generics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Drug Class

9.3.3.2.2.            By Application

9.3.3.2.3.            By Distribution Channel

10.  Middle East and Africa Branded Generics Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti – Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)

10.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)

10.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

10.2.4. By Country

10.3.   MEA: Country Analysis

10.3.1. South Africa Branded Generics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Drug Class

10.3.1.2.2.         By Application

10.3.1.2.3.         By Distribution Channel

10.3.2. Saudi Arabia Branded Generics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Drug Class

10.3.2.2.2.         By Application

10.3.2.2.3.         By Distribution Channel

10.3.3. UAE Branded Generics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Drug Class

10.3.3.2.2.         By Application

10.3.3.2.3.         By Distribution Channel

11.  Market Dynamics

11.1.   Drivers

11.2.   Challenges

12.  Market Trends & Developments

12.1.   Recent Development

12.2.   Mergers & Acquisitions

12.3.   Product Launches

13.  Global Branded Generics Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.   Competition in the Industry

14.2.   Potential of New Entrants

14.3.   Power of Suppliers

14.4.   Power of Customers

14.5.   Threat of Substitute Products

15.  Competitive Landscape

15.1.   Business Overview

15.2.   Product Offerings

15.3.   Recent Developments

15.4.   Financials (As Reported)

15.5.   Key Personnel

15.6.   SWOT Analysis

15.6.1    Teva Pharmaceutical Industries Ltd.

15.6.2    Lupin Pharmaceuticals Inc.

15.6.3    Sanofi-Aventis.

15.6.4    Sun Pharmaceutical Industries Inc.

15.6.5    Dr Reddy's Laboratories Inc.

15.6.6    Endo International PLC.

15.6.7    GlaxoSmithKline LLC.

15.6.8    Pfizer Inc.

15.6.9    Viatris Inc.

15.6.10  Apotex Inc.

16.  Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Branded Generics Market was estimated to be USD 230.02 Billion in 2022.

down-arrow

The retail pharmacy segment demonstrated significant dominance in 2022, primarily driven by the growing burden of chronic diseases and the various discounts offered by retail pharmacies are boosting the market growth.

down-arrow

North America emerged as the dominant market in 2022, capturing a significant revenue share. High penetration of branded generic drugs and the growing disease burden and geriatric population are also likely to fuel the market growth.

down-arrow

Rising prevalence of chronic diseases, increasing penetration of branded generic drugs, increasing government initiatives to promote generic products, and patent expiry of major drugs are the major drivers for the Global Branded Generics Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Branded Generics Market to be dominated by Anti – Hypertensive Drugs through 2028

Oct, 2023

Increasing penetration of branded generic drugs is expected to drive the Global Branded Generics Market growth in the forecast period, 2024-2028.

Why Choose Us